Importantly, beneficial effects of SGLT2 inhibition were also demonstrated in nondiabetic kidney disease such as hypertensive nephropathy and were attributed to anti-inflammatory effects [27]. This evidence concerns the gene SLC5A2 and hypertensive nephropathy.